The Efficacy of Bleomycin Sclerotherapy in the Treatment of Low-Flow Vascular Malformation
DOI:
https://doi.org/10.59675/U316Keywords:
Low-flow venous malformations, Bleomycin sclerotherapy, Vascular anomalies, Thrombotic response.Abstract
Background: Low-flow venous malformations (VMs) are a class of vascular anomalies that are recognized by dilated or ectatic, thin-walled channels that are often involved with cosmetic sensitive areas or functionally crucial areas. Sclerotherapy has become the mainstay of treatment, and bleomycin is of great interest for its safety and efficacy.
Objective: To evaluate the clinical outcomes, safety, and thrombotic response associated with ultrasound-guided bleomycin foam sclerotherapy in patients with low-flow VMs.
Methods: In this prospective, single-center study, 23 patients (mean age 25.22 ± 17.30 years; 52.2% female) were treated at a triage practice in Baghdad. All patients received ultrasound-guided bleomycin foam injections intralesionally with a standardized maximum of 5 mg/session. The number of sessions (1-6 sessions), pre- treatment and post-treatment lesion sizes, and the development of a thrombotic reaction were recorded. Clinical outcomes were assessed using Doppler ultrasound and clinical examination at a four-month follow-up.
Results: Lesion location was predominantly on the face (43.5%), in addition to some involvement on the limbs and trunk. Most patients required one or two treatment sessions (Mean ± SD: 2.52 ± 1.50). Statistically significant decreases in dimensions were shown for the lesions (D1: decreased by 0.93 cm (p = 0.001) & D2 decreased by 0.66 cm (p = 0.001)). Complete thrombosis of their lesion occurred in 56.5% of cases, with partial regression in the rest. No significant complications occurred. The only minor adverse effects reported were transient erythema and local swelling (11.5%).
Conclusion: Bleomycin sclerotherapy safely and effectively treats low-flow VMs, producing significant volumetric reduction and thrombotic response with limited morbidity. This data support its wider use in mixed-anatomical presentations, particularly where aesthetic or functional outcomes are vital.
Downloads
References
Budge EJ, Khalil Allam MA, Mechie I, Scully M, Agu O, Lim CS. Venous malformations: Coagulopathy control and treatment methods. Phlebology. 2021;36(5):361-74. DOI: https://doi.org/10.1177/0268355520972918
Colmenero I, Knöpfel N. Venous malformations in childhood: clinical, histopathological and genetics update. Dermatopathology. 2021;8(4):477-93. DOI: https://doi.org/10.3390/dermatopathology8040050
Kim H, Joh J, Labropoulos N. Characteristics, clinical presentation, and treatment outcomes of venous malformation in the extremities. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2022;10(1):152-8. DOI: https://doi.org/10.1016/j.jvsv.2021.05.011
Ahlawat S, Fayad LM, Durand DJ, Puttgen K, Tekes A. International society for the study of vascular anomalies classification of soft tissue vascular anomalies: survey-based assessment of musculoskeletal radiologists’ use in clinical practice. Current problems in diagnostic radiology. 2019;48(1):10-6. DOI: https://doi.org/10.1067/j.cpradiol.2017.10.003
Tawfik HA, Dutton JJ. Orbital vascular anomalies: a nomenclatorial, etiological, and nosologic conundrum. Ophthalmic Plastic & Reconstructive Surgery. 2022;38(2):108-21. DOI: https://doi.org/10.1097/IOP.0000000000002029
Putra J, Al-Ibraheemi A. Vascular anomalies of the head and neck: a pediatric overview. Head and Neck Pathology. 2021;15(1):59-70. DOI: https://doi.org/10.1007/s12105-020-01236-x
Zhou J, Zhao Z, Sun T, Liu W, Yu Z, Liu J, et al. Efficacy and safety of sirolimus for blue rubber bleb nevus syndrome: a prospective study. Official journal of the American College of Gastroenterology| ACG. 2021;116(5):1044-52. DOI: https://doi.org/10.14309/ajg.0000000000001117
Beijnen UE, Saldanha F, Ganske I, Upton J, Taghinia AH. Verrucous venous malformations of the hand. Journal of Hand Surgery (European Volume). 2019;44(8):850-5. DOI: https://doi.org/10.1177/1753193419845271
Borst AJ, Nakano TA, Blei F, Adams DM, Duis J. A primer on a comprehensive genetic approach to vascular anomalies. Frontiers in Pediatrics. 2020;8:579591. DOI: https://doi.org/10.3389/fped.2020.579591
Butnariu LI, Gorduza EV, Florea L, Țarcă E, Moisă ȘM, Trandafir LM, et al. The Genetic Architecture of Vascular anomalies: current data and future therapeutic perspectives correlated with Molecular mechanisms. International Journal of Molecular Sciences. 2022;23(20):12199. DOI: https://doi.org/10.3390/ijms232012199
Weitz-Tuoretmaa A. Low-Flow Vascular Malformations: Genetics and Quality of Life after Endovascular Sclerotherapy. 2022.
Schmidt VF, Cangir Ö, Meyer L, Goldann C, Hengst S, Brill R, et al. Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children. European Radiology. 2024;34(10):6425-34. DOI: https://doi.org/10.1007/s00330-024-10723-6
Tiwary SK. Investigations in Vascular Malformations. Vascular Malformations. 2021:105-25. DOI: https://doi.org/10.1007/978-981-15-9762-6_11
Gibson CR, Barnacle AM. Vascular anomalies: special considerations in children. CVIR endovascular. 2020;3(1):60. DOI: https://doi.org/10.1186/s42155-020-00153-y
Soulez G, Gilbert P, Giroux M-F, Racicot J-N, Dubois J. Interventional management of arteriovenous malformations. Techniques in Vascular and Interventional Radiology. 2019;22(4):100633. DOI: https://doi.org/10.1016/j.tvir.2019.100633
Al-Antary ET, Gupte A, Carter J, Kaafarani M, Howard M, Edwards H, et al. Curing childhood cancer the “Natural” Way: Nature as the source of chemotherapy agents. Biochemical Pharmacology. 2023;213:115630. DOI: https://doi.org/10.1016/j.bcp.2023.115630
Gembillo G, Ingrasciotta Y, Crisafulli S, Luxi N, Siligato R, Santoro D, et al. Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia. International journal of molecular sciences. 2021;22(9):4824. DOI: https://doi.org/10.3390/ijms22094824
Kang M, Connor DE, Parsi K. Treatment of venous malformations with tumescent-assisted sclero-embolic and ablative lasers (SEALs): safe and effective long-term outcomes. Phlebology. 2022;37(5):367-80. DOI: https://doi.org/10.1177/02683555221080045
Lin S-N, Wu Y-M, Siow T-Y, Yeh C-H, Toh C-H, Tseng T-Y, et al. Sclerotherapy with intralesional bleomycin injection under guidance of multi-slice CT for retrobulbar orbital low-flow vascular lesions—single-center experience. British Journal of Radiology. 2024;97(1153):186-94. DOI: https://doi.org/10.1093/bjr/tqad008
Brandão PS, Jacinto J, Rodrigues H, Bouça A, Mateus C, Reis J, et al. Intralesional bleomycin sclerotherapy for head and neck low-flow vascular malformations—A retrospective single-center experience. Journal of Cranio-Maxillofacial Surgery. 2025. DOI: https://doi.org/10.1016/j.jcms.2024.12.015
Yang Y, Sun M, Ma Q, Cheng X, Ao J, Tian L, et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. Journal of vascular surgery. 2011;53(1):150-5. DOI: https://doi.org/10.1016/j.jvs.2010.07.019
Redkar RG, Chigicherla S, Joshi S, Bangar A, Tewari S. Efficacy of intralesional bleomycin as an alternative approach in the management of vascular anomalies. Saudi Surgical Journal. 2017;5(2):60-4. DOI: https://doi.org/10.4103/ssj.ssj_4_17
Nevesny F, Chevallier O, Falvo N, Guillen K, Malakhia A, Pellegrinelli J, et al. Bleomycin for percutaneous sclerotherapy of venous and lymphatic malformations: a retrospective study of safety, efficacy and mid-term outcomes in 26 patients. Journal of Clinical Medicine. 2021;10(6):1302. DOI: https://doi.org/10.3390/jcm10061302
Sainsbury DC, Kessell G, Fall AJ, Hampton FJ, Guhan A, Muir T. Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. Plastic and reconstructive surgery. 2011;127(5):2031-44. DOI: https://doi.org/10.1097/PRS.0b013e31820e923c
Spence J, Krings T, TerBrugge KG, Agid R. Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy. Head & neck. 2011;33(1):125-30. DOI: https://doi.org/10.1002/hed.21410
Agid N, Itsekzon Ze, Hendriks EJ, Terbrugge K, Agid R. Bleomycin sclerotherapy for venous vascular malformations of the tongue. Journal of NeuroInterventional Surgery. 2025. DOI: https://doi.org/10.1136/jnis-2024-022713
De Maria L, De Sanctis P, Balakrishnan K, Tollefson M, Brinjikji W. Sclerotherapy for venous malformations of head and neck: systematic review and meta-analysis. Neurointervention. 2020;15(1):4-17. DOI: https://doi.org/10.5469/neuroint.2019.00213
Horbach S, Van De Ven J, Nieuwkerk P, Spuls PI, Van Der Horst C, Reekers J. Patient-reported outcomes of bleomycin sclerotherapy for low-flow vascular malformations and predictors of improvement. Cardiovascular and interventional radiology. 2018;41:1494-504. DOI: https://doi.org/10.1007/s00270-018-1999-8
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Academic International Journal of Medical Update
This work is licensed under a Creative Commons Attribution 4.0 International License.
